Amneal stock: buy or sell?
August 23rd, 2019
Should I buy Amneal stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Amneal Pharmaceuticals stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Amneal stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we collected 15 ratings published for AMRX stock in the last month. The general sentiment of these ratings is bullish for AMRX stock, with 9 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-6||BMO Capital Markets||n/a||Market Perform|
|2019-7-8||Piper Jaffray Companies||Neutral||Overweight|
|2019-7-22||Svb Leerink||Market Perform||Outperform|
|2019-7-11||Royal Bank of Canada||Outperform||Sector Perform|
|2019-5-21||Raymond James||Market Perform||Strong-Buy|
|2019-3-8||Svb Leerink||Outperform||Market Perform|
|2019-3-8||Leerink Swann||n/a||Market Perform|
Amneal stock analysis
Shares of Amneal Pharmaceuticals closed today at $2.52 and plunged a chilling -5.97%.
Amneal Pharmaceuticals ended today at $2.52 and plunged a chilling -5.97%. Since May when AMRX stock price broke down the SMA100d line, it slid $-10.92 per share (-81.25%).
After sliding a hair-raising -20.25% in a week last week, Amneal Pharmaceuticals closed this week at $2.52 and soared a pretty good 4.13%. Late July AMRX boosted an exceptional 6.85% in just one week.
Since price and 20-weeks moving average lines crossed down early May, AMRX fell $-11.17 per share (-81.59%).
Amneal stock price history
Amneal IPO was on May 7th, 2018 at $17.00 per share1. Since then, AMRX stock lost a -85.20%, with a yearly average of -85.20%.
1: Adjusted price after possible price splits or reverse-splits.
Amneal stock historical price chart
AMRX stock reached all-time highs with a price of $24.48.
Amneal stock price target is $11.30Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 11 price targets for Amneal stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-6||BMO Capital Markets||Lowers Target||$6.00||$5.00||-16.7%|
|2019-7-8||Piper Jaffray Companies||Upgrades||n/a||$11.00||-|
|2019-7-11||Royal Bank of Canada||Downgrades||$11.00||$6.00||-45.5%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on May, Amneal collapsed a hair-raising -77.17%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Amneal Pharmaceuticals annual turnover climbed an amazing 60.89% to $1,662.99 million dollars from $1,033.65 marked in 2017. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) decreased a -1.26% to -1.26%. Amneal fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Amneal TTM sales up to were $1,387.80 and earnings $-20.92 million dollars. If we compare this TTM figures with the last reported annuality, we can review Amneal Pharmaceuticals business evolution since December 2018: Annual turnover up to , compared to lastest yearly report, plunged a scary -16.55%. Regarding profit margin, Amneal remained stable -0.25% to -1.26%
|2013||$512 M||-||$101 M19.8%||-|
|2014||$596 M||16.53%||$57 M9.6%||-43.36%|
|2015||$860 M||44.36%||$39 M4.5%||-32.00%|
|2016||$1,018 M||18.33%||$0.00 M0.0%||-100.00%|
|2017||$1,034 M||1.52%||$0.00 M0.0%||0.00%|
|2018||$1,663 M||60.89%||$-20.92 M-1.3%||0.00%|
|TTM||$1,388 M||-16.55%||$-20.92 M-1.5%||0.00%|
Quarterly financial resultsAmneal posted M in revenues for 2019-Q1, a -100.00% decline compared to previous quarter. Reported quarter income marked million with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was -1.76%. When comparing turnover to same quarter last year, Amneal Pharmaceuticals sales marked a tight movement and stayed constant a nan%.
|2017-Q1||$184 M||-||$-98.43 M-53.4%||-|
|2017-Q2||$260 M||40.93%||$37.45 M14.4%||-138.04%|
|2017-Q3||$255 M||-1.98%||$0.00 M0.0%||-100.00%|
|2017-Q4||$183 M||-28.20%||$-301.07 M-164.6%||0.00%|
|2018-Q2||$414 M||126.22%||$-19.10 M-4.6%||-93.65%|
|2018-Q3||$476 M||15.15%||$6.95 M1.5%||-136.39%|
|2018-Q4||$498 M||4.42%||$-8.77 M-1.8%||-226.12%|
Amneal ownershipWhen you are planning to invest in a company, it's worth to review its ownership structure.
Amneal Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 36.79% of all shares.
Bearish positions for AMRX stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$291.1 M|
|Total shares||115.5 M|
|Float shares||32.9 M|
|- Institutional holdings (%)||101.5%|
|- Insider holdings (%)||36.8%|
|Shares in short selling||0.0%|
|Friday, August 23rd, 2019|
|Day range||$2.51 - $2.71|
|Average true range||$0.23|
|50d mov avg||$4.46|
|100d mov avg||$7.63|
|200d mov avg||$11.18|
Amneal performanceTo better understand Amneal performance you must becnhmark its gains with other related stocks in same sector or industry. We picked as the bechmarking frame for Amneal Pharmaceuticals stock.